BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Jeffrey Dunn	Professor of Clinical Neurology, Neurology and Neurological Sciences Co-Director, Stanford MS Center/Neuroimmunology Clinic
eRA COMMONS USER NAME (credential, e.g., agency login) Dunn.Jeffrey	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	MM/YY	FIELD OF STUDY
Haverford College; Haverford, PA	BA	1983	French Literature
Temple University School of Medicine; Phila., PA	MD	1989	Medicine
University of Washington; Seattle, WA	Residency	1993	Neurology

Please refer to the application instructions in order to complete sections A, B, C, and D of the Biographical Sketch.

A. Personal Statement

I specialize in the diagnosis, treatment, and clinical research of Multiple Sclerosis, Neuromyelitis Optica, Transverse Myelitis, and immunologically mediated diseases of the human nervous system. As Director of the Neurology Clerkship and Clinical Neuroimmunology Fellowship, I am involved in Neurology clinical education of medical students, interns, housestaff officers, and fellows.

B. Positions and Honors

Academic Positions Held:

1992-1993	Chief Resident in Neurology, University of Washington; Seattle, WA
1993-1996	Clinical Instructor in Medicine (Neurology), University of Washington; Seattle, WA
2000-2004	Ward and Consult Attending, Puget Sound VA Medical Center; Seattle, WA
1997-2007	Assistant Professor of Clinical Neurology; University of Washington; Seattle, WA
2008-2012	Associate Professor of Clinical Neurology, Stanford University; Stanford, CA
2013-present	Professor of Clinical Neurology, Stanford University; Stanford, CA
2008-present	Neurology Clerkship Director, Stanford University; Stanford, CA
2008-present	Co-Director, Stanford MS/Neuroimmunology Clinic; Stanford, CA
2011-present	Chair, MS Education Workgroup, Multiple Sclerosis General Section American Academy of Neurology; St. Paul, MN
2010-present	Executive Committee, MS General Section Councilor American Academy of Neurology; peer elected 2010, peer re-elected 2012
2008-2010	Chairman, Clinical Advisory Committee, Nor-Cal Chapter NMSS; SF, CA
2008-present	Member, Association of University Professors of Neurology

Awards and Honors:

2008	Fellow, American Academy of Neurology
2008-2012	Neurology Clerkship Student Teaching Award; Stanford University
2008-2009	Lysia Forno Award for Outstanding Departmental Teaching; Stanford University Department of Neurology; Stanford, CA

2009-2010 Excellence in Teaching Award; Stanford University School of Medicine
2011 Arthur L. Bloomfield Award for Excellence in teaching Clinical Medicine; Stanford University School of Medicine; Stanford, CA
2011 Successful Recruitment Award for highest percentage match of graduating medical students matching to Neurology; Association of University Professors of Neurology; Minneapolis, MN
2012 Successful Recruitment Award for highest percentage match of graduating medical students matching to Neurology; Association of University Professors of Neurology; Minneapolis, MN
1998-2007 "America's Top Physicians," Consumers' Research Council of America
2010-2013 "America's Top Physicians," Consumers' Research Council of America

C. Peer Reviewed Publications

1. Herges K, deJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ro RM, Maini A, Han, MH, Killestein J. Polman C, Goodyear A, **Dunn J**, Steinman L, Axtell RC; Protective effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. *Multiple Sclerosis* 2012; 18 (4): 398-408
2. **Dunn J**., Blight D. Dalfampridine: A Brief Review of Its Mechanism of Action and Efficacy as a Treatment to Improve Walking in Patients With Multiple Sclerosis; *Curr Med Res Opin. 2011* Jul;27(7):1415-23
3. **Dunn J**. The impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis. *Expert Rev Pharmaoecon Outcomes Res*: 2010 Aug; 10 (4) 433-440
4. Pershing S., **Dunn J.,** Khan A., Liao JY (2009). CMV Optic Neuritis with extensive tracking along the visual pathway. *J Neuro-Ophthalmology*, 29 (3):223-226.
5. Fox EJ and the **TERMS Study Investigators** (2008). Tovaxin for early relapsing Multiple Sclerosis phase 2b Placebo controlled trial of autologous T cell vaccination in patients with CIS or MS. *Multiple Sclerosis*, (14);S5-S27.
6. Arnold D., Campagnolo D., Panitch H., Bar-Or A., **Dunn J.,** Freedman M., Gazda S.K., Vollmer T. (2008). Glatiramer Acetate after Mitoxantrone Induction Improves MRI Markers of lesion volume and permanent tissue injury in MS. *J Neurol,* 255, 1473-1478.
7. Vollmer T., Panitch H., Bar-Or A., **Dunn J.,** Freedman M.S., Gazda S.K., Campagnolo D., Deutsch F., Arnold D. (2008). Glatiramer Acetate after induction therapy with mitoxantrone in relapsing Multiple Sclerosis. *Multiple Sclerosis,* 14, 663-670.
8. Cohen J.A. and the **9006 Study Group** (2007). A randomized, double blind, dose comparison study of glatiramer acetate in relapsing remitting Multiple Sclerosis. *Neurology*, 68(12),939-944.
9. Cohen J.A., Rovaris M., and the **9006 Study Group** (2006). Results of a randomized, double blind, parallel group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI measured disease activity in relapsing remitting Multiple Sclerosis. *Neurology*, 67,185.
10. **Dunn J.,** Kita M., Lucas S., Bowen J (2001). Novantrone in the treatment of Multiple Sclerosis. *Alliance News*, 1,1-3.
11. **Dunn J.,** Maidan R., Pallis J. Gingko Biloba in the treatment of Alzheimer's Disease (1998). *Alternative Medicine*, 1(15), 1-2.
12. Bursell, J., Odderson I., **Dunn J.** Atherosclerotic aortic disease as a source of embolic infarct (1996). *Journal of Neurovascular Disease*, 1(2), 35-38.
13. Spach D., Panther L., Thorning D., **Dunn J.,** Plorde J., Miller R. (1992). Intracerebral Bacillary Angiomatosis in a patient infected with HIV. *Annals of Internal Medicine*. 116, 740-743.

14. **Research Support**

    1. Accelerated Cure Project; Principal Investigator
       A longitudinal, case control study to collect medical and epidemiological data and blood samples for research into the causes of Multiple Sclerosis and selected demyelinating diseases; 10/13/09-present
    2. Translational Research Grant; Co-Principal Investigator

Blood and CSF repository to identify biomarkers in Multiple Sclerosis; 9/09-present

3. National Multiple Sclerosis Society; Co-Investigator
   "A randomized controlled trial of vitamin D in multiple sclerosis." 2012-present
4. Roche; Principal Investigator,
   "A Randomized Double Blind Double Dummy Parallel Group Study to Evaluate the Efficacy of Ocrelizumab in Comparison to Interferon beta in Patients with relapsing Multiple Sclerosis; 2012-present
5. Actelion; Principal Investigator
   Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients with Relapsing-remitting Multiple Sclerosis; 2010-present
6. Genzyme; Principal Investigator
   A Phase III randomized rater and dose blinded study comparing two annual cycles of intravenous low and high dose alemtuzumab to three times weekly subcutaneous interferon beta-1a in patients with relapsing remitting Multiple Sclerosis who have relapsed on therapy. 7/09-present
7. NIH; CombiRx Study; Principal Investigator, site
   A multi-center, double blind randomized study comparing the combined use of interferon beta 1a and glatiramer acetate to either agent alone in patients with relapsing remitting Multiple Sclerosis. 9/05-2/08